Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4194134 | 0.92 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNAPOLBCHRM2CHRM1 | |
| SCHEMBL30241901 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNAPOLBCHRM2CHRM1 | |
| SCHEMBL3656085 | 0.85 | POLB (0.43) | SMN1; SMN2LMNAPOLBCHRM2CHRM1 | |
| SCHEMBL4012966 | 0.81 | ALDH1A1 (0.50) | SMN1; SMN2LMNAPOLBCHRM2CHRM1 | |
| SCHEMBL5196109 | 0.81 | LMNA (0.52) | SMN1; SMN2LMNAPOLBCHRM2CHRM1 | |
| SCHEMBL3313643 | 0.81 | SMN1; SMN2 (0.52) | SMN1; SMN2LMNAPOLBCHRM2CHRM1 | |
| SCHEMBL31532476 | 0.81 | LMNA (0.41) | SMN1; SMN2LMNAPOLBCHRM2CHRM1 | |
| SCHEMBL3689756 | 0.80 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAPOLBCHRM2CHRM1 | |
| SCHEMBL16256877 | 0.80 | LMNA (0.58) | SMN1; SMN2LMNAPOLBCHRM2CHRM1 | |
| SCHEMBL725320 | 0.80 | LMNA (0.58) | SMN1; SMN2LMNAPOLBCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4334303-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2022235715-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| EP-2560955-B1 | NOVEL BENZAMIDE DERIVATIVES | DONG A PHARM CO LTD (KR) | 2016-06-29 | — | — | EP | disclosed |
| US-9221790-B2 | Benzamide derivatives | DONG-A PHARM. CO., LTD. (KR) | 2015-12-29 | — | — | US | disclosed |
| US-20130085160-A1 | NOVEL BENZAMIDE DERIVATIVES | DONG-A PHARM. CO., LTD. (KR) | 2013-04-04 | — | — | US | disclosed |
| EP-2560955-A2 | NOVEL BENZAMIDE DERIVATIVES | Dong-A Pharm.Co., Ltd. (KR) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011132901-A2 | NOVEL BENZAMIDE DERIVATIVES | DONG-A PHARM.CO., LTD. (KR) | 2011-10-27 | — | — | WO | disclosed |
| EP-0777660-A1 | NOVEL ALKYLAMINO DERIVATIVES AS SIGMA 2 SELECTIVE LIGANDS | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996005185-A1 | NOVEL ALKYLAMINO DERIVATIVES AS SIGMA 2 SELECTIVE LIGANDS | MITSUBISHI CHEMICAL CORPORATION (JP) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085160-A1 | NOVEL BENZAMIDE DERIVATIVES | HTR4, GPR4, HTR5A | SMN1; SMN2 1290/4885LMNA 4050/4885POLB 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.